About: An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
Creator	Zhou, Bin Massare, Michael Glenn, Gregory Smith, Gale Flyer, David Fries, Louis Lu, Hanxin Raghunandan, Rama Xabier, Mimi
Source	Elsevier; Medline; PMC
abstract	Abstract Post-infectious immunity to respiratory syncytial virus (RSV) infection results in limited protection as evidenced by the high rate of infant hospitalization in the face of high titer, maternally derived RSV-specific antibodies. By contrast, RSV fusion (F) glycoprotein antigenic site II humanized monoclonal antibodies, palivizumab and motavizumab, have been shown to reduce RSV-related hospitalization in infants. Immunogenicity and efficacy studies were conducted in cotton rats comparing a recombinant RSV F nanoparticle vaccine with palivizumab and controlled with live RSV virus intranasal immunization and, formalin inactivated RSV vaccine. Active immunization with RSV F nanoparticle vaccine containing an alum adjuvant induced serum levels of palivizumab competing antibody (PCA) greater than passive administration of 15mg/kg palivizumab (human prophylactic dose) in cotton rats and neutralized RSV-A and RSV-B viruses. Immunization prevented detectable RSV replication in the lungs and, unlike passive administration of palivizumab, in the nasal passage of challenged cotton rats. Histology of lung tissues following RSV challenge showed no enhanced disease in the vaccinated groups in contrast to formalin inactivated ‘Lot 100’ vaccine. Passive intramuscular administration of RSV F vaccine-induced immune sera one day prior to challenge of cotton rats reduced viral titers by 2 or more log10 virus per gram of lung and nasal tissue and at doses less than palivizumab. A recombinant RSV F nanoparticle vaccine protected lower and upper respiratory tract against both RSV A and B strain infection and induced polyclonal palivizumab competing antibodies similar to but potentially more broadly protective against RSV than palivizumab.
has issue date	2014-11-12(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2014.09.030
bibo:pmid	25269094
has license	els-covid
sha1sum (hex)	3602faa031e21257cfdb816ab5f1b58d2d0eef54
schema:url	https://doi.org/10.1016/j.vaccine.2014.09.030
resource representing a document's title	An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization
has PubMed Central identifier	PMC7172787
has PubMed identifier	25269094
schema:publication	Vaccine
resource representing a document's body	covid:3602faa031e21257cfdb816ab5f1b58d2d0eef54#body_text
is schema:about of	named entity 'viral' named entity 'hospitalization' named entity 'intramuscular' named entity 'site' named entity 'administration' named entity 'detectable' named entity 'day' named entity 'titer' named entity 'high' named entity 'administration' named entity 'palivizumab' named entity 'reduce' named entity 'studies' named entity 'antibodies' named entity 'respiratory syncytial virus' named entity 'active' covid:arg/3602faa031e21257cfdb816ab5f1b58d2d0eef54 named entity 'RSV' named entity 'prophylactic' named entity 'nanoparticle' named entity 'cotton' named entity 'vaccine' named entity 'infection' named entity 'prevented' named entity 'RSV' named entity 'human' named entity 'antibody' named entity 'RSV' named entity 'lung' named entity 'log' named entity 'polyclonal' named entity 'immune sera' named entity 'passive' named entity 'rats' named entity 'cotton' named entity 'efficacy' named entity 'vaccine' named entity 'cell' named entity 'antibodies' named entity 'Immunization' named entity 'nasal passage' named entity 'palivizumab' named entity 'palivizumab' named entity 'prophylactic' named entity 'monoclonal antibodies' named entity 'antigenic site' named entity 'recombinant' named entity 'RSV' named entity 'RSV' named entity 'immunization' named entity 'RSV' named entity 'upper respiratory tract' named entity 'intranasal' named entity 'palivizumab' named entity 'viral titers' named entity 'Immunogenicity' named entity 'RSV' named entity 'passive immunization' named entity 'cotton' named entity 'antibodies' named entity 'LOD' named entity 'protein' named entity 'supernatant' named entity 'palivizumab' named entity 'infection' named entity 'GMT' named entity 'antibody' named entity 'vaccine' named entity 'RSV' named entity 'vaccine' named entity 'neutralizing antibodies' named entity 'RSV' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software